The neoadjuvant approach in breast cancer treatment: It is not just about chemotherapy anymore

Current Opinion in Obstetrics and Gynecology

Volumn 23, Issue 1, 2011, Pages 31-36

  Caudle, Abigail S ^a   Hunt, Kelly K ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

breast cancer; neoadjuvant chemotherapy; tumor response

Indexed keywords

DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE; LETROZOLE; METFORMIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; AFRICAN AMERICAN; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; BREAST CARCINOMA; BREAST CONSERVATION THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER THERAPY; DIABETES MELLITUS; DRUG EFFICACY; EVENT FREE SURVIVAL; HEART FAILURE; HUMAN; INVASIVE DUCTAL CARCINOMA; INVASIVE LOBULAR CARCINOMA; LYMPH NODE DISSECTION; MAMMOGRAPHY; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE CARE; PRIORITY JOURNAL; RISK FACTOR; SENTINEL LYMPH NODE BIOPSY; TREATMENT RESPONSE; TUMOR VOLUME;

BIOMEDICAL RESEARCH; BREAST NEOPLASMS; FEMALE; HUMANS; NEOADJUVANT THERAPY; TREATMENT OUTCOME;

EID: 78651443057     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/GCO.0b013e3283416477     Document Type: Article

References (32)

1. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16:2672-2685. (Pubitemid 28363030)
2. Rastogi P, Anderson S, Bear H, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008; 26:778-785. (Pubitemid 351264391)
3. Bear H, Anderson S, Smith R, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006; 24:2019-2027. (Pubitemid 46622110)
4. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997; 15:2479-2482. (Pubitemid 27289876)
5. Hunt K, Yi M, Mittendorf E, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg 2009. [Epub ahead of print]
6. Juul N, Szallasi Z, Eklund A, et al. Assessment of an RNA interference screenderived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet Oncol 2010; 11:358-365.
7. Lee J, Coutant C, Kim Y, et al. Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res 2010; 16:711-718.
8. Caudle A, Gonzalez-Angulo A, Hunt K, et al. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28:1821-1828.
9. Faneyte I, Schrama J, Peterse J, et al. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 2003; 88:406-412. (Pubitemid 36308152)
10. Dowsett M, Dunbier A. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res 2008; 14:8019-8026.
11. Tubiana-Hulin M, Stevens D, Lasry S, et al. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. Ann Oncol 2006; 17:1228-1233. (Pubitemid 44288213)
12. Cristofanilli M, Gonzalez-Anguo A, Sneige N, et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 2005; 23:41-48. (Pubitemid 41702621)
13. Boughey J, Wagner J, Garrett B, et al. Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservation. Ann Surg Oncol 2009; 16:1606-1611.
14. Purushotham A, Pinder S, Cariati M, et al. Neoadjuvant chemotherapy: not the best option in estrogen receptor-positive, HER2-negative, invasive classical lobular carcinoma of the breast? J Clin Oncol 2010; 28:3552-3554.
15. Straver M, Rutgers E, Rodenhuis S, et al. The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol 2010; 17:2411-2418.
16. Chang HR, Glaspy J, Allison MA, et al. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. Cancer 2010; 116:4227-4237.
17. Larsson S, Mantzoros C, Wolk A. Diabetes mellitus and risk of breast cancer: a metaanalysis. Int J Cancer 2007; 121:856-862. (Pubitemid 47106217)
18. Yancik R, Wesley M, Ries L, et al. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 2001; 285:885-892. (Pubitemid 32171549)
19. Jiralerspong S, Palla S, Giordano S, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009; 27:3297-3302.
20. Smith I, Procter M, Gelber R, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369:29-36. (Pubitemid 46039831)
21. Romond E, Perez E, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673-1684. (Pubitemid 41464706)
22. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010; 375:377-384.
23. Buzdar A, Valero V, Ibrahim N, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007; 13:228-233. (Pubitemid 46121873)
24. Mittendorf E, Wu Y, Scaltriti M, et al. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 2009; 15:7381-7388.
25. Colleoni M, Bagnardi V, Rotmensz N, et al. Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy. Breast Cancer Res Treat 2009; 116:359-369.
26. (EBCTCG), E.B.C.T.C.G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-1717. (Pubitemid 40719106)
27. Semiglazov VF, Semiglazov VV, Dashyan GA, et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer 2007; 110: 244-254. (Pubitemid 47121883)
28. Olson J, Budd G, Carey L, et al. Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. J Am Coll Surg 2009; 208:906-914.
29. Dose-Schwarz J, Tiling R, Avril-Sassen S, et al. Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer. Br J Cancer 2010; 102:35-41.
30. Soucy G, Belanger J, LeBlanc G, et al. Surgical margins in breast-conservation operations for invasive carcinoma: does neoadjuvant chemotherapy have an impact? J Am Coll Surg 2008; 206:1116-1121.
31. Wagner J, Boughey J, Garrett B, et al. Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer. Am J Surg 2009; 198:387-391.
32. Daveau C, Savignoni A, Abrous-Anane S, et al. Is radiotherapy an option for early breast cancers with complete clinical response after neoadjuvant chemotherapy? Int J Radiat Oncol Biol Phys 2010. [Epub ahead of print]